Laryngeal cancer

Cancer originating in the larynx (voice box)

Medical condition

Laryngeal cancer

Other names| Cancer of the larynx, laryngeal carcinoma
Larynx cancer – endoscopic view
Specialty| Oncology, otorhinolaryngology
Deaths| 94,800 (2018) [1]

Laryngeal cancer is a kind of cancer that can develop in any part of the larynx (voice box). It is typically a squamous-cell carcinoma, reflecting its origin from the epithelium of the larynx.

The prognosis is affected by the location of the tumour. For the purposes of staging, the larynx is divided into three anatomical regions: the glottis (true vocal cords, anterior and posterior commissures); the supraglottis (epiglottis, arytenoids and aryepiglottic folds, and false cords); and the subglottis. Most laryngeal cancers originate in the glottis, with supraglottic and subglottic tumours being less frequent.

Laryngeal cancer may spread by: direct extension to adjacent structures, metastasis to regional cervical lymph nodes, or via the blood stream. The most common site of distant metastases is the lung. Laryngeal cancer occurred in 177,000 people in 2018, and resulted in 94,800 deaths (an increase from 76,000 deaths in 1990).[1][2] Five-year survival rates in the United States are 60.3%.[3]

## Signs and symptoms

[edit]

The symptoms of laryngeal cancer depend on the size and location of the tumour. Symptoms may include the following:[4][5]

* Hoarseness or other voice changes
* A lump in the neck
* A sore throat or feeling that something is stuck in the throat
* Persistent cough
* Stridor \- a high-pitched wheezing sound indicative of a narrowed or obstructed airway
* Bad breath
* Earache (due to referred pain)
* Difficulty swallowing

Adverse effects of treatment can include changes in appearance, difficulty eating, dry mouth, or loss of voice that may require learning alternate methods of speaking.[6]

## Risk factors

[edit]

The most important risk factor for laryngeal cancer is tobacco smoking. Death from laryngeal cancer is 20 times more likely for the heaviest smokers than for their non-smoking peers.[7] Regular and heavy consumption of alcohol, particularly alcoholic spirits, is also a significant risk factor. Using alcohol and tobacco together is an especially high risk factor and causes 89% of laryngeal cancer cases.[8][9]

Occupational exposure to environmental factors such as wood dust, paint fumes, and certain chemicals used in the metalworking, petroleum, plastics, and textile industries[10] is also believed to be a risk factor for laryngeal cancers. Infections by some forms of HPV carry some risk of laryngeal carcinoma.[11]

People with a history of head and neck cancer are known to be at higher risk (about 25%) of developing a second, separate cancer of the head, neck, or lung. This is likely due to chronic exposure to the carcinogenic effects of alcohol and tobacco. In this situation, a field change effect may occur, where the epithelial tissues start to become diffusely dysplastic with a reduced threshold for malignant change. This risk may be reduced by quitting alcohol and tobacco.[citation needed]

## Diagnosis

[edit]

Larynx and nearby structures
Cavitas nasi: Nasal cavity
Cavis orum: oral cavity
Glottis: Larynx
Plica vocalis: Vocal cords
Trachea
Oesophagus: Esophagus

Diagnosis is made by the doctor on the basis of a medical history, physical examination, and special investigations which may include a chest x-ray, CT or MRI scans, and tissue biopsy. The examination of the larynx requires some expertise, which may require specialist referral.[citation needed]

The physical exam includes a systematic examination of the whole patient to assess general health and to look for signs of associated conditions and metastatic disease. The neck and supraclavicular fossa are palpated to feel for cervical adenopathy, other masses, and laryngeal crepitus. The oral cavity and oropharynx are examined under direct vision. The larynx may be examined by indirect laryngoscopy using a small angled mirror with a long handle (akin to a dentist's mirror) and a strong light. Indirect laryngoscopy can be highly effective, but requires skill and practice for consistent results. For this reason, many specialist clinics now use fibre-optic nasal endoscopy where a thin and flexible endoscope, inserted through the nostril, is used to clearly visualise the entire pharynx and larynx. Nasal endoscopy is a quick and easy procedure performed in clinic. Local anaesthetic spray may be used.[citation needed]

If there is a suspicion of cancer, biopsy is performed, usually under general anaesthetic. This provides histological proof of cancer type and grade. If the lesion appears to be small and well localised, the surgeon may undertake excision biopsy, where an attempt is made to completely remove the tumour at the time of first biopsy. In this situation, the pathologist will not only be able to confirm the diagnosis, but can also comment on the completeness of excision, i.e., whether the tumour has been completely removed. A full endoscopic examination of the larynx, trachea, and esophagus is often performed at the time of biopsy.[citation needed]

For small glottic tumours further imaging may be unnecessary. In most cases, tumour staging is completed by scanning the head and neck region to assess the local extent of the tumour and any pathologically enlarged cervical lymph nodes.

The final management plan will depend on the site, stage (tumour size, nodal spread, distant metastasis), and histological type. The overall health and wishes of the patient must also be taken into account. A prognostic multigene classifier has been shown to be potentially useful for the distinction of laryngeal cancer of low or high risk of recurrence and might influence the treatment choice in future.[12]

## Staging

[edit]

Laryngeal tumours are classified according to the guidelines set by academic organisations such as the National Comprehensive Cancer Network (NCCN) .[13] Overall classification, also known as "staging", can help predict treatment options for patients.[14] Staging consists of three separate evaluations. The first is of the tumour/cancer itself ("T").[14] The second is the extent to which adjacent lymph nodes are involved in the tumour/cancer's spread ("N").[14] The third is the presence or absence of any distant metastases ("M).[14] The specific “staging” criteria for laryngeal cancer, as utilised in the NCCN’s 2019 Guidelines for Head and Neck Cancers,[15] are:

### T

[edit]

TX: Unable to assess

Tis: Carcinoma in situ

#### Supraglottis

[edit]

T1: Tumour present in only one subsite of the supraglottis. Vocal cords have normal mobility.

T2: Tumour invades mucosa. There is no fixation of the larynx.

T3: Tumour causes fixation of the vocal cords, with or without invasion of neighbouring areas.

T4:

* T4A – Tumour invades at least one of the following: the outer cortex of the thyroid cartilage, extra-laryngeal tissue
* T4B – Tumour invades at least one of the following: the pre-vertebral space, any structures of the mediastinum, the carotid sheath, or the structures within the carotid sheath.

#### Glottis

[edit]

T1: Tumour only involves the vocal cords. Vocal cords have normal mobility.

* T1A – One vocal cord
* T1B – Both vocal cords

T2: Tumour meets at least one of the following criteria:

* extends to supra- or sub-glottis
* impairs vocal cord mobility

T3: Tumour meets at least one of the following criteria:

* causes fixation of the vocal cords
* invades the paraglottic space
* involves the thyroid cartilage’s inner cortex

T4: Same as “Supraglottis”

#### Subglottis

[edit]

T1: Tumour is only in the subglottis

T2: Tumour involves both subglottis and vocal cords (regardless of cord mobility)

T3: Same as “Glottis”

T4: Same as “Supraglottis”

### N

[edit]

If Using Clinical (Non-Pathological) Diagnosis

NX: Unable to assess

N0: No involvement of neighbouring lymph nodes

N1: Tumour meets ALL of the following criteria:

* involves single lymph node
* involved lymph node on the same side of the body as tumour
* involved lymph node less than 3 cm in “greatest dimension”
* lacks extension beyond the lymph node

N2: Tumour meets ANY of the following criteria

* N2A – Same as N1, except size can be between 3–6 cm
* N2B – Same as N2A, except lymph nodes can be multiple, and there is no minimum size
* N2C – Same as N2B, except lymph nodes can be on any side of the body

N3: Tumour meets ANY of the following criteria:

* N3A – Same as N1, except size is greater than 6 cm
* N3B – Tumour obviously extends beyond the lymph node border (regardless of number, size, or location of lymph nodes)

If Using Pathological Diagnosis

NX: Same as “Clinical Diagnosis – NX”

N0:  Same as “Clinical Diagnosis – N0”

N1:  Same as “Clinical Diagnosis – N1”

N2: Tumour meets ANY of the following criteria

* N2A – Same as “Clinical Diagnosis – N2A”, except tumour can extend beyond the involved lymph node
* N2B – Same as “Clinical Diagnosis – N2B”
* N2C – Same as “Clinical Diagnosis – N2C”

N3: Tumour meets ANY of the following criteria:

* N3A – Same as “Clinical Diagnosis – N3A”
* N3B – Any provable presence of tumour extension beyond the lymph node

### M

[edit]

M0: No evidence of distant metastasis

M1: Evidence of distant metastasis

## Treatment

[edit]

Removed larynx, containing cancerous tissue

Specific treatment depends on the location, type, and stage of the tumour.[16] Treatment may involve surgery, radiotherapy, or chemotherapy, alone or in combination.[16]

Surgical Treatment

Surgical treatment may involve partial or full removal of the tumour.[17] Neighbouring tissues and structures may or may not be removed, depending on their involvement in the tumour’s structure and spread.[18] Full removal of the larynx may be necessary in some cases.

Adjunct Treatment

Adjunct treatment, most commonly the administration of chemotherapy or radiotherapy, may be necessary.[18] Chemotherapy or radiotherapy may be necessary singly, in combination with each other, or in combination with surgery.[15] Adjunct treatment may be necessary prior to surgical treatment, alongside surgical treatment, or after surgical treatment. Clinical decision-making can be difficult in circumstances where the patient is unable to access necessary adjunct treatment.

Multi-Disciplinary Treatment

Often, successful treatment of and recovery from laryngeal cancer will involve expertise outside of the realms of surgery or oncology. Physical therapists, occupational therapists, speech therapists, psychiatrists, psychologists, oral/maxillofacial surgeons, dentists, neurologists, neurosurgeons, and endocrinologists may all become involved in the care of patients with laryngeal cancer.

## Epidemiology

[edit]

Incidence is five in 100,000 (12,500 new cases per year) in the US.[19] The American Cancer Society estimated that 9,510 men and women (7,700 men and 1,810 women) would be diagnosed with and 3,740 men and women would die of laryngeal cancer in 2006.[citation needed]

According to the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, there were 177,422 new cases of laryngeal cancer worldwide in 2018 (1.0% of the global total.) Among worldwide cancer deaths, 94,771 (1.0%) were due to laryngeal cancer. [20]

In 2019, it is estimated that there will be 12,410 new laryngeal cancer cases in the United States, (3.0 per 100,000).[21] The number of new cases decreases every year at a rate of 2.4%,[21] and this is believed to be related to decreased cigarette smoking in the general population.[22]

Laryngeal cancer is listed as a "rare disease" by the Office of Rare Diseases (ORD) of the National Institutes of Health (NIH). This means that laryngeal cancer affects fewer than 200,000 people in the US.[23]

## See also

[edit]

* Voice prosthesis

## References

[edit]

1. ^ a b "Larynx Cancer Factsheet" (PDF). Global Cancer Observatory. Archived (PDF) from the original on 8 November 2019. Retrieved 8 November 2019.
2. ^ Naghavi M, Wang H, Lozano R, Davis A, Liang X, Zhou M, et al. (GBD 2013 Mortality and Causes of Death Collaborators) (January 2015). "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013". Lancet. 385 (9963): 117–171\. doi:10.1016/S0140-6736(14)61682-2. PMC 4340604. PMID 25530442.
3. ^ "SEER Stat Fact Sheets: Larynx Cancer". NCI. Archived from the original on 17 October 2019. Retrieved 22 January 2020.
4. ^ Laryngeal cancer Archived 2009-04-15 at the Wayback Machine at Mount Sinai Hospital
5. ^ DeVita VT, Lawrence TS, Rosenberg SA (2011). Devita, Hellman, and Rosenberg's cancer : principles & practice of oncology (10th ed.). Philadelphia. ISBN 978-1-4511-9294-0.`{{cite book}}`: CS1 maint: location missing publisher (link)
6. ^ "Cancer of the Larynx - Causes, Symptoms, Treatment, Diagnosis - MedBroadcast.com". Archived from the original on 2015-10-18. Retrieved 2018-01-25.
7. ^ Ridge JA, Glisson BS, Lango MN, Feigenberg S, Horwitz EM (2008). "Head and neck tumors.". In Pazdur R, Wagman LD, Camphausen KA, Hoskins W (eds.). Cancer management: a multidisciplinary approach (PDF). Vol. 11\. p. 369\. Archived (PDF) from the original on 2022-10-02. Retrieved 2021-11-09.
8. ^ Gormley, Mark; Creaney, Grant; Schache, Andrew; Ingarfield, Kate; Conway, David I. (2022-11-11). "Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors". British Dental Journal. 233 (9): 780–786\. doi:10.1038/s41415-022-5166-x. ISSN 0007-0610. PMC 9652141. PMID 36369568.
9. ^ Hashibe, Mia; Brennan, Paul; Chuang, Shu-chun; Boccia, Stefania; Castellsague, Xavier; Chen, Chu; Curado, Maria Paula; Dal Maso, Luigino; Daudt, Alexander W.; Fabianova, Eleonora; Fernandez, Leticia; Wünsch-Filho, Victor; Franceschi, Silvia; Hayes, Richard B.; Herrero, Rolando (2009-02-01). "Interaction between Tobacco and Alcohol Use and the Risk of Head and Neck Cancer: Pooled Analysis in the International Head and Neck Cancer Epidemiology Consortium". Cancer Epidemiology, Biomarkers & Prevention. 18 (2): 541–550\. doi:10.1158/1055-9965.EPI-08-0347. ISSN 1055-9965. PMC 3051410. PMID 19190158.
10. ^ "Laryngeal Cancer". Archived from the original on December 9, 2022. Retrieved April 7, 2019.
11. ^ Torrente MC, Rodrigo JP, Haigentz M, Dikkers FG, Rinaldo A, Takes RP, et al. (April 2011). "Human papillomavirus infections in laryngeal cancer". Head & Neck. 33 (4). Head Neck: 581–586\. doi:10.1002/hed.21421. PMID 20848441. S2CID 30274997.
12. ^ Mirisola V, Mora R, Esposito AI, Guastini L, Tabacchiera F, Paleari L, et al. (August 2011). "A prognostic multigene classifier for squamous cell carcinomas of the larynx". Cancer Letters. 307 (1): 37–46\. doi:10.1016/j.canlet.2011.03.013. PMID 21481529.
13. ^ "National Comprehensive Cancer Network – Home". NCCN. Archived from the original on 2023-02-13. Retrieved 2020-11-24.
14. ^ a b c d Amin M, Edge S, Greene F, et al. (2017). AJCC Cancer Staging Manual. New York: Springer.
15. ^ a b Pfister DG, Spencer S, Adelstein D, Adkins D, Anzai Y, Brizel DM, et al. (July 2020). "Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology". Journal of the National Comprehensive Cancer Network. 18 (7): 873–898\. doi:10.6004/jnccn.2020.0031. PMID 32634781. S2CID 220405484.
16. ^ a b National Comprehensive Cancer Network, "Evidence Blocks for Head and Neck Cancers," 2019.
17. ^ Nibu KI, Hayashi R, Asakage T, Ojiri H, Kimata Y, Kodaira T, et al. (August 2017). "Japanese Clinical Practice Guideline for Head and Neck Cancer". Auris, Nasus, Larynx. 44 (4): 375–380\. doi:10.1016/j.anl.2017.02.004. PMID 28325607.
18. ^ a b Grégoire V, Lefebvre JL, Licitra L, Felip E (May 2010). "Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Annals of Oncology. 21 (Suppl 5): v184–86. doi:10.1093/annonc/mdq185. hdl:2434/577016. PMID 20555077.
19. ^ Beenken SW. "Laryngeal Cancer (Cancer of the larynx)". Armenian Health Network, Health.am. Archived from the original on 2020-11-27. Retrieved 2007-03-22.
20. ^ Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (November 2018). "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries". CA: A Cancer Journal for Clinicians. 68 (6). Wiley: 394–424\. doi:10.3322/caac.21492. PMID 30207593. S2CID 52188256.
21. ^ a b "Cancer Stat Facts: Larynx Cancer". Archived from the original on 2022-11-22. Retrieved 2019-08-09.
22. ^ "Throat Cancer Statistics | Cases of Throat Cancer Per Year". www.cancer.org. Archived from the original on 2019-07-27. Retrieved 2020-12-04.
23. ^ "Annual Report on the Rare Diseases and Conditions Research". National Institutes of Health. Archived from the original on 2010-12-03. Retrieved 2007-03-22.

## External links

[edit]

Classification|

* ICD-10: C32
* ICD-9-CM: 161
* MeSH: D007822

|

External resources|

* Patient UK: Laryngeal cancer
* NCI: Laryngeal cancer

* Staging cancer of the larynx
* Cancer Management Handbook: Head and Neck Cancers Archived 2013-10-04 at the Wayback Machine
* Clinically reviewed laryngeal cancer information for patients, from Cancer Research UK
* UK laryngeal cancer statistics from Cancer Research UK

* v
* t
* e

Cancer involving the respiratory tract

Upper RT|

Nasal cavity
Esthesioneuroblastoma

Nasopharynx
Nasopharyngeal carcinoma
Nasopharyngeal angiofibroma

Larynx
Laryngeal cancer
Laryngeal papillomatosis

Lower RT|

| Trachea|

* Tracheal tumor

|

Lung|

| Non-small-cell lung carcinoma|

* Squamous-cell carcinoma
* Adenocarcinoma (Mucinous cystadenocarcinoma)
* Large-cell lung carcinoma
* Rhabdoid carcinoma
* Sarcomatoid carcinoma
* Carcinoid
* Salivary gland–like carcinoma
* Adenosquamous carcinoma
* Papillary adenocarcinoma
* Giant-cell carcinoma
* Basaloid squamous cell lung carcinoma

|

Small-cell carcinoma|

* Combined small-cell carcinoma

Non-carcinoma|

* Sarcoma
* Lymphoma
* Immature teratoma
* Melanoma

By location|

* Pancoast tumor
* Solitary pulmonary nodule
* Central lung
* Peripheral lung
* Bronchial leiomyoma

Pleura|

* Mesothelioma
* Malignant solitary fibrous tumor

Mediastinum|

* Mediastinal tumors

Authority control databases

National|

* Germany
* United States
* Japan
* Czech Republic
* Israel

Other|

* Yale LUX

*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template